

Caphosol®

What is Caphosol®?


Caphosol® is an electrolyte solution for the prevention and treatment of oral mucositis, which is also known as stomatitis among some health care professionals. Caphosol® is indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or chemotherapy. Caphosol® is also indicated for dryness of the mouth and oropharynx (hyposalivation and

xerostomia) regardless of the cause or whether the conditions are temporary or permanent.¹

Caphosol® contains high concentrations of calcium and phosphate ions. Calcium and phosphate are important in maintaining a healthy oral cavity.² Caphosol® is designed to moisten, lubricate and clean the oral cavity including the mucosa of mouth, tongue and oropharynx.¹

How can Caphosol® improve oral mucositis?


The safety and efficacy of Caphosol® in treating oral mucositis has been clinically demonstrated.²



Adapted from Papas et al.² Data from a prospective, randomised, double-blind, controlled trial of 95 patients undergoing bone marrow transplantation.

Caphosol® was shown to:

- Reduce the duration of oral mucositis²
- Reduce the duration of pain associated with oral mucositis²
- Reduce morphine use in patients by 72%, with nearly three quarters requiring no morphine at all²




Adapted from Papas et al.² Data from a prospective, randomised, double-blind, controlled trial of 95 patients undergoing bone marrow transplantation.

Through preventing and treating oral mucositis associated with cancer therapies, the risk of interrupting cancer treatment is reduced.

How can Caphosol® prevent oral mucositis?


Caphosol® has been shown to have a clinically significant impact on the occurrence and severity of oral mucositis in two open-label studies.^{3,4}

The first was an observational registry, which noted low rates of oral mucositis in chemotherapy and radiation patients at high risk of developing oral mucositis, who performed an oral rinse 4-10 times daily with prophylactic Caphosol®.³



Adapted from Haas *et al.*³ Open label, observational registry in head and neck patients (n=61) receiving chemo- and/or radiation therapy at 26 radiation/medical oncology sites throughout the USA from August 2007 to February 2008.

The second found Caphosol® was associated with reductions in the incidence and severity of oral mucositis, in addition to reductions in treatment costs.⁴



Adapted from Miyamoto C *et al.*⁴ A retrospective study of 21 head and neck cancer patients treated with intensity-modulated radiation therapy (IMRT) who received Caphosol® from the start of their treatment. Outcomes were compared with 21 matched control patients who received standard care for oral mucositis.

- Caphosol® reduces requirement for feeding tubes⁴
- Caphosol® reduces oral mucositis-related hospitalisation⁴
- Caphosol® reduces oral mucositis-related treatment costs by 54-68%, depending upon the model used to estimate treatment costs⁴

How is Caphosol® used?

Caphosol® can be easily integrated into overall cancer therapy

- Very easy to use and comes in two different coloured ampoules¹
 - One ampoule contains the phosphate ions and the other contains the calcium ions
- Well tolerated²
- Flexible dosing from 4 to 10 times a day, depending on patient's need¹

To use Caphosol® properly there are a few simple steps¹

1 Mix the two ampoules together in a glass*



2 Swish with half of the liquid for one full minute



3 Spit out



4 Swish again with the other half for another full minute



5 Spit out



*Ampoules do not need to be poured simultaneously into a glass

References:

1. Caphosol® Product information. EUSA Pharma (Europe) Limited, November 2008.
2. Papas AS *et al.* *Bone Marrow Transplant* 2003;**31**:705–712.
3. Haas M *et al.* 50th ASTRO congress 2008; abstract 2530.
4. Miyamoto C *et al.* *Support Care Cancer* 2009;**17**:857–1039.